“ Don’t play what’s there... Play what’s not there !
Miles Davis
While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, companies often lacks the necessary funding to bring medicines and healthcare technology to market.
Edge & Walker
Facilitating strategic connections that drive life sciences dealmaking.
What is your investment potential in the US ?
Getting answer to this question is a key factor for success for European Biotechs because the United States is a crucial source for growth capital.
US Biotechs receive almost five times as much private funding as their European counterparts do.
The United States is the biggest source of funding (Private/Public) for European Biotechs with global aspirations.
Biotech IPOs are three times larger on Nasdaq than on European exchanges.
The biotech venture financing gap between Europe and the US is growing, with European investors known to be more conservative when investing in non-revenue generating companies compared with those in the US.
US-based biotech venture financing for innovator drugs reached a total of $72bn from 2017 to 2022, while Europe raised only $16bn*.
*Source : GlobaData Healthcare
Unlock unlimited potential and elevate your gain.
In an OPEN INNOVATION approach, Edge & Walker helps you open up your innovation process to external potential stakeholders.
Benefits of such approach include faster access to new relevant technology, the opportunity to explore new market opportunities, improved identification of relevant licensing partners, and boosted value creation.
